Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $157.67 Average Price Target from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have earned a consensus rating of "Buy" from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $157.67.

Several analysts recently commented on KRYS shares. Citigroup raised their target price on Krystal Biotech from $160.00 to $195.00 and gave the stock a "buy" rating in a report on Tuesday, February 27th. Cantor Fitzgerald raised their target price on Krystal Biotech from $160.00 to $180.00 and gave the stock an "overweight" rating in a report on Wednesday, December 13th. Guggenheim raised their target price on Krystal Biotech from $130.00 to $175.00 and gave the stock a "buy" rating in a report on Tuesday, February 27th. Finally, William Blair reiterated an "outperform" rating on shares of Krystal Biotech in a research report on Tuesday, February 27th.

Insiders Place Their Bets

In other news, CAO Kathryn Romano sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $130.00, for a total value of $325,000.00. Following the transaction, the chief accounting officer now owns 12,556 shares in the company, valued at $1,632,280. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares in the company, valued at $265,138,786.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $130.00, for a total value of $325,000.00. Following the completion of the transaction, the chief accounting officer now owns 12,556 shares in the company, valued at approximately $1,632,280. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,587 shares of company stock worth $6,535,591. 17.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. lifted its position in Krystal Biotech by 50.0% during the second quarter. PNC Financial Services Group Inc. now owns 372 shares of the company's stock worth $44,000 after buying an additional 124 shares in the last quarter. Osaic Holdings Inc. lifted its position in Krystal Biotech by 193.3% during the second quarter. Osaic Holdings Inc. now owns 396 shares of the company's stock worth $46,000 after buying an additional 261 shares in the last quarter. Almanack Investment Partners LLC. purchased a new position in Krystal Biotech during the third quarter worth approximately $52,000. West Tower Group LLC lifted its position in Krystal Biotech by 413.1% during the fourth quarter. West Tower Group LLC now owns 431 shares of the company's stock worth $53,000 after buying an additional 347 shares in the last quarter. Finally, KBC Group NV purchased a new position in Krystal Biotech during the fourth quarter worth approximately $59,000. Hedge funds and other institutional investors own 86.29% of the company's stock.

Krystal Biotech Trading Down 1.0 %

Shares of KRYS stock traded down $1.86 during mid-day trading on Monday, reaching $176.07. The stock had a trading volume of 365,529 shares, compared to its average volume of 399,107. The business's fifty day moving average is $143.56 and its 200-day moving average is $124.60. The firm has a market cap of $4.98 billion, a price-to-earnings ratio of 2,200.88 and a beta of 0.86. Krystal Biotech has a 1-year low of $77.10 and a 1-year high of $189.97.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, February 26th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of ($0.52) by $0.82. The company had revenue of $42.14 million for the quarter, compared to analyst estimates of $27.43 million. During the same period last year, the business earned ($1.25) earnings per share. On average, analysts forecast that Krystal Biotech will post 1.61 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).